Anti-IL23alpha Neutralizing Antibody

BPS Bioscience

Anti-IL23alpha Neutralizing Antibody

7

Neutralisation/Blocking

Research Use Only

Monoclonal

≥90%

IL23A

interleukin 23 subunit alpha

IL-23; IL-23 subunit alpha; IL-23A; IL-23-A; IL23P19; IL-23p19; interleukin 23 p19 subunit; interleukin 23, alpha subunit p19; interleukin-23 subunit alpha; interleukin-23 subunit p19; interleukin-six, G-CSF related factor; JKA3 induced upon T-cell activation; P19; SGRF

Human

Interleukin-23 subunit alpha

This purified recombinant monoclonal antibody is a human anti-IL23alpha that selectively binds to the p19 subunit of heterodimeric IL-23, which is composed of p19 and IL-12 p40. The variable regions for this antibody are based on an FDA-approved drug Skyrizi® (risankizumab-rzaa), sold by AbbVie. This antibody has been tested for specific binding affinity to IL23alpha/IL12beta antigen.

-80°C

12352203